APP intracellular domain derived from amyloidogenic β- and γ-secretase cleavage regulates neprilysin expression
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by an accumulation of Amyloid-β (Aβ), released by sequential proteolytic processing of the amyloid precursor protein (APP) by β - and γ-secretase. Aβ peptides can aggregate, leading to toxic Aβ oligomers and amyloid plaque formation. Aβ accumulation is not only dependent on de novo synthesis but also on Aβ degradation. Neprilysin (NEP) is one of the major enzymes involved in Aβ degradation. Here we investigate the molecular mechanism of NEP regulation, which is up to now controversially discussed to be affected by APP processing itself. We found that NEP expression is highly dependent on the APP intracellular domain (AICD), released by APP processing. Mouse embryonic fibroblasts devoid of APP processing, either by the lack of the catalytically active subunit of the γ-secretase complex [presenilin (PS) 1/2] or by the lack of APP and the APP-like protein 2 (APLP2), showed a decreased NEP expression, activity and protein level. Similar results were obtained by utilizing cells lacking a functional AICD domain (APPΔCT15) or expressing mutations in the genes encoding for PS1. AICD supplementation or retransfection with an AICD encoding plasmid could rescue the down-regulation of NEP further strengthening the link between AICD and transcriptional NEP regulation, in which Fe65 acts as an important adaptor protein. Especially AICD generated by the amyloidogenic pathway seems to be more involved in the regulation of NEP expression. In line, analysis of NEP gene expression in vivo in six transgenic AD mouse models (APP and APLP2 single knock-outs, APP/APLP2 double knock-out, APP-swedish, APP-swedish/PS1Δexon9, and APPΔCT15) confirmed the results obtained in cell culture. In summary, in the present study we clearly demonstrate an AICD-dependent regulation of the Aβ-degrading enzyme NEP in vitro and in vivo and elucidate the underlying mechanisms that might be beneficial to develop new therapeutic strategies for the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · cited 1×
“Resulting fluorescence was measured at an excitation wavelength of 320 ± 10 nm and an emission wavelength of 405± 10 nm in a Safire2 Fluorometer as described above.”
MethodCitron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., et al. (1997) · Nature Medicine · doi:10.1038/nm0197-67 · Cited by 1,271
Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867
γ-Secretase, notch, Aβ and alzheimer's disease: Where do the presenilins fit in?
Sisodia, S. S., & St George-Hyslop, P. H. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn785 · Cited by 512
Ring, S., Weyer, S. W., Kilian, S. B., Waldron, E., Pietrzik, C. U., Filippov, M. A., Herms, J., Buchholz, C., Eckman, C. B., Korte, M., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1026-07.2007 · Cited by 390 · cited 2×
“To elucidate the impact of AICD onNEP expression, we analyzed APP knock-in MEF devoid of full-length APP, expressing an APP construct lacking the last 15 aa from the C-terminus (MEF APP1CT15) (Ring et al., 2007).”
BackgroundMethodLiu, Q., Zerbinatti, C. V., Zhang, J., Hoe, H.-S., Wang, B., Cole, S. L., Herz, J., Muglia, L., & Bu, G. (2007) · Neuron · doi:10.1016/j.neuron.2007.08.008 · Cited by 364
Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo
Miller, B. C., Eckman, E. A., Sambamurti, K., Dobbs, N., Chow, K. M., Eckman, C. B., Hersh, L. B., & Thiele, D. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031520100 · Cited by 294 · cited 1×
“…of the endogenous AICD isoforms are rarely detected, because of their rapid degradation in the cytosol by insulin degrading enzyme (IDE) (Edbauer et al., 2002; Farris et al., 2003; Miller et al., 2003), the proteasome (Nunan et al., 2003) and Cathepsin B (Vingtdeux et al., 2007; Asai et al., 2011).”
BackgroundFelsenstein, K. M., Hunihan, L. W., & Roberts, S. B. (1994) · Nature Genetics · doi:10.1038/ng0394-251 · Cited by 90
Schieb, H., Kratzin, H., Jahn, O., Möbius, W., Rabe, S., Staufenbiel, M., Wiltfang, J., & Klafki, H. W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.246561 · Cited by 65
Cited by
Polyphenols as Potential Metal Chelation Compounds Against Alzheimer’s Disease
Lakey-Beitia, J., Burillo, A. M., La Penna, G., Hegde, M. L., & Rao, K. S. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-200185 · Cited by 177
“Further cleaving of CTFα by γ-secretase leads to formation of protein 3 (p3), a soluble and neuroprotective peptide [99, 100].”
A Greek Tragedy: The Growing Complexity of Alzheimer Amyloid Precursor Protein Proteolysis
Andrew, R. J., Kellett, K. A. B., Thinakaran, G., & Hooper, N. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.746032 · Cited by 173
Amyloid-β oligomers in cellular models of Alzheimer’s disease
Fontana, I. C., Zimmer, A. R., Rocha, A. S., Gosmann, G., Souza, D. O., Lourenco, M. V., Ferreira, S. T., & Zimmer, E. R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15030 · Cited by 115
“PC12 cells Synthetic and Endogenous AβOs 0.01 – 20 • Distinct LMW and HMW AβOs toxicity (McKoy et al., 2012); • Antibody inhibits Aβ toxicity (Lambert et al., 2001); • GLP-1 neuroprotection (Batista et al., 2018); • ↑ Cytosolic calcium through NMDAr (Gilson et al., 2015); • ↑ γ-secretase activity (Wencel et al., 2017)…”
InfluentialAPP Function and Lipids: A Bidirectional Link
Grimm, M. O. W., Mett, J., Grimm, H. S., & Hartmann, T. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00063 · Cited by 104
“However, we demonstrated in two recent studies that several tocopherol and tocotrienol species have beside their protective antioxidative properties the undesirable effect of increasing amyloidogenic APP processing and reducing the enzymatic degradation of Aβ-peptides (Grimm et al., 2015b, 2016c).”
BackgroundInfluentialSelf-citationBukhari, H., Glotzbach, A., Kolbe, K., Leonhardt, G., Loosse, C., & Müller, T. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.05.005 · Cited by 88
Metadata
- Authors
- Grimm, M. O. W., Mett, J., Stahlmann, C. P., Grösgen, S., Haupenthal, V. J., Blümel, T., Hundsdörfer, B., Zimmer, V. C., Mylonas, N. T., Tanila, H., Müller, U., Grimm, H. S., & Hartmann, T.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2015-05-19
- Volume
- 7
- Pages
- 77-77
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W1602872921
- Cited by
- 65
- References
- 11
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.